VectivBio Announces Pricing of $125 Million Underwritten : c

BASEL, Switzerland, Oct. 13, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company...

Related Keywords

Minnesota , United States , New York , Boston , Massachusetts , Switzerland , Marshall Wace , Patrick Malloy , Piper Sandler , Forbion Growth Opportunities Fund , Exchange Commission , Exchange Commission On Form , Strategic Communications , Prospectus Department , Eventide Asset Management , Equity Syndicate Prospectus Department , Piper Sandler Co , Syndicate Department , Vectivbio Holding Ag Nasdaq , Frazier Life Sciences , Cowen Healthcare Investments , Driehaus Capital Management , Growth Opportunities Fund , Surveyor Capital , Venrock Healthcare Capital Partners , Vivo Capital , Acute Graft Versus Host Disease , Inherited Metabolic Diseases , Risk Factor , Registration Statement , Annual Report , Bio Contacts , Investor Relations , Nasdaq Vect , Ectivbio Ag ,